Portal portfolio company, Syntax Bio expands its Series A to $14.4 million

Congratulations to our Chicago-based portfolio company, Syntax Bio, on expanding its Series A to $14.4 million and surpassing $25 million in total funding. Syntax is advancing the frontiers of regenerative medicine through its Cellgorithm™ platform and pioneering pancreatic beta cell therapies for type 1 diabetes.